We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byKylie Zimmerman
Modified over 3 years ago
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 Access, Capacity Building and R&D: IFPMA Member Company Programs to help improve Health in Developing Countries ECOSOC, Geneva, 8 July 2009
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 2 Growing Industry Effort to help achieve MDGs Additional Initiatives Chronic Diseases Child & Maternal Preventable Diseases Tropical Diseases MalariaMalaria TuberculosisTuberculosis HIV/AIDSHIV/AIDS Section 9 9 8 8 1111 1212 2424 2006 64 1111 1717 1010 1919 1313 1313 5252 2007 135 TOTALS 2020 2323 1212 1818 1414 1414 5454 2008 155 + 21 (26)(26) 2424 2929 1515 2121 1717 1616 5454 2009 176 (202)
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 3 Industry Programs for Access… and more Industry Partnerships to Improve Health in Developing World What the programs are doing: Access (36 % of all programs)Access (36 % of all programs) Capacity-Building (55 % of all programs)Capacity-Building (55 % of all programs) Education (32 % of all programs)Education (32 % of all programs) R&D for DDW* (23 % of all programs)R&D for DDW* (23 % of all programs) (* DDW = Diseases of the Developing World) (NOTE: Many programs have more than 1 area of activity)
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 4 Example: HIV / AIDS Abbott, Boehringer-Ingelheim, Johnson & Johnson Abbott, Boehringer-Ingelheim, Johnson & Johnson Partners: Elizabeth Glaser Pediatric AIDS Foundation Partners: Elizabeth Glaser Pediatric AIDS Foundation Access – Donation Access – Donation Capacity Building – Training Capacity Building – Training Education Education In 17 Developing Countries In 17 Developing Countries Elizabeth Glaser Pediatric AIDS Foundation Trains Health WorkersTrains Health Workers HIV counselingHIV counseling Prevention educationPrevention education Infant feeding educationInfant feeding education Donation of ARVs for PMTCTDonation of ARVs for PMTCT Donation of rapid test kitsDonation of rapid test kits
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 5 Example: Tuberculosis Eli Lilly and Company Eli Lilly and Company Partners: WHO & Others Partners: WHO & Others Access – Pricing & Licensing Access – Pricing & Licensing Capacity Building – Support & Training Capacity Building – Support & Training Education Education In 60 developing countries In 60 developing countries Lilly MDR-TB Partnership Access to medicinesAccess to medicines Production Technology TransferProduction Technology Transfer Training Health WorkersTraining Health Workers Disease SurveillanceDisease Surveillance Educating People at RiskEducating People at Risk Community SupportCommunity Support
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 6 Example: Malaria Pfizer Pfizer Partner: London School of Hygiene & Tropical Medicine, KEMRI- Wellcome Trust, Health Partners Ghana & others Partner: London School of Hygiene & Tropical Medicine, KEMRI- Wellcome Trust, Health Partners Ghana & others Capacity Building – Support & Training Capacity Building – Support & Training In Ghana, Kenya, Senegal In Ghana, Kenya, Senegal Mobilize Against Malaria Training Health WorkersTraining Health Workers Technical AssistanceTechnical Assistance Material supportMaterial support Sharing Best PracticesSharing Best Practices
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 7 Example: Tropical Diseases Merck KGaA Merck KGaA Partner: Programme for Research & Training in Tropical Diseases (TDR), sponsored by UNICEF, UNDP, World Bank & WHO Partner: Programme for Research & Training in Tropical Diseases (TDR), sponsored by UNICEF, UNDP, World Bank & WHO Research & Development Research & Development Merck Serono Collaboration with TDR Training ResearchersTraining Researchers Malaria & Sleeping SicknessMalaria & Sleeping Sickness Screening Compound LibraryScreening Compound Library Identify new Lead MoleculesIdentify new Lead Molecules
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 8 Example: Preventable Diseases Crucell, GlaxoSmithKline, Merck & Co, sanofi-aventis, Wyeth Crucell, GlaxoSmithKline, Merck & Co, sanofi-aventis, Wyeth Partners: GAVI Alliance, WHO & other partners Partners: GAVI Alliance, WHO & other partners Access – Donation & Pricing Access – Donation & Pricing Capacity Building – Support & Training Capacity Building – Support & Training In many low-income countries In many low-income countries GAVI Alliance Existing / new vaccines to LDCsExisting / new vaccines to LDCs Preferential pricing of vaccinesPreferential pricing of vaccines Donation of vaccinesDonation of vaccines Technical & Training SupportTechnical & Training Support
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 9 Example: Child & Maternal Health Schering-Plough Schering-Plough Partners: WHO Regional Office for Africa, International Federation of Gynecology & Obstetrics (FIGO) Partners: WHO Regional Office for Africa, International Federation of Gynecology & Obstetrics (FIGO) Capacity Building – Training Capacity Building – Training 10 countries in Africa & Latin America 10 countries in Africa & Latin America Postpartum Hemorrhage Training Material Postpartum management guidePostpartum management guide For low resource environmentsFor low resource environments Complementary posters, etc.Complementary posters, etc. In English, French & SpanishIn English, French & Spanish
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 10 Example: Chronic Diseases Novo Nordisk & Roche Novo Nordisk & Roche Partners: World Diabetes Federation, Ministries of Health & patient organizations Partners: World Diabetes Federation, Ministries of Health & patient organizations Access – Donation Access – Donation Capacity Building – Support & Training Capacity Building – Support & Training Cameroon, DR Congo, Guinea, Tanzania, Uganda Cameroon, DR Congo, Guinea, Tanzania, Uganda Changing Diabetes in Children Develop infrastructureDevelop infrastructure Train Health WorkersTrain Health Workers Guidelines & Education MaterialGuidelines & Education Material Medicines & Medical SuppliesMedicines & Medical Supplies
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 11 Example: Additional Health Initiatives Japanese Pharmaceutical Manufacturers Association (JPMA) Japanese Pharmaceutical Manufacturers Association (JPMA) Partners: WHO, Thailand Ministry of Health Partners: WHO, Thailand Ministry of Health Capacity Building – Support & Training Capacity Building – Support & Training Bhutan, Cambodia, Laos, Thailand Bhutan, Cambodia, Laos, Thailand Strengthening Quality Control in SE Asia Improve Medicine QualityImprove Medicine Quality Train Government PersonnelTrain Government Personnel Provide Analytical InstrumentsProvide Analytical Instruments Supply Reference SubstancesSupply Reference Substances
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 12 www.ifpma.org/healthpartnerships Search by Developing Country: Kenya 43 programs found
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 13 www.globalhealthprogress.org Find Details of Partner Organizations that Industry works with in different areas…
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 14 Number of Active Research and Development Projects* *1 project = 1 compound in development or 1 screening program for 1 disease Medicine R&D projects Vaccine R&D projects Source: IFPMA IFPMA Status Report on DDW R&D - 2009 R&D for TDR 10 Priority Diseases: - Chagas - Dengue - Human African Trypanosomiasis - Leishmaniasis - Leprosy - Lymphatic Filariasis - Malaria - Onchocerciasis - Schistosomiasis - Tuberculosis
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 15 Overview of R&D Projects by Disease Area – 2009 Disease Ongoing Medicines R&D Projects Ongoing Vaccines R&D Projects Approvals Since 2005 R&D Projects Stopped Since 2005 Tuberculosis22306 Malaria304212 Other Tropical Diseases 23232 Totals759520
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 16 Developing World Disease R&D Funders 2007 US Government 48.9 % US Government 48.9 % Bill & Melinda Gates Foundation 17.7 % Pharma Industry 9.1 % European Commission 4.7 % United Kingdom (Govt) 3.9 % Wellcome Trust 2.3 % Netherlands (Govt) 1.3 % Pasteur Institute 1.2% Ireland (Govt) 0.9 % Brazil (Govt) 0.9 % Sweden (Govt) 0.8 % Canada (Govt) 0.7% Australia (Govt) 0.7 % Russia (Govt) 0.7 % Belgium (Govt) 0.6 % France (Govt) 0.5 % South Africa (Govt) 0.2 % All Other Philanthropic 1.0 % All Other Govts 4.4 % Source: G-FINDER, George Institute, 2009 © IFPMA 2009ECOSOC R&D and Access 08 July 2009
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 17 www.ifpma.org/clinicaltrials Terms to search for: Malaria & Vaccine Trials conducted in: Kenya
© IFPMA 2009ECOSOC R&D and Access 08 July 2009 Thank You! Ch. Louis-Dunant 15 P.O. Box 195 121211 Geneva 20 Switzerland Tel: +41-22-338 32 00 Fax:+41-22-338 32 99 Email: firstname.lastname@example.org Web:www.ifpma.org
© IFPMA 2009WIPO Open-ended Forum on Proposed Development Agenda Projects - 13/10/2009 IFPMA views on the strategic use of information for sustainable.
How fractions, decimals and percentages work together.
R&D Financing by the Bill & Melinda Gates Foundation
European HIV/AIDS programmes: EDCTP as a model of Europe-Africa partnership 19 July 2011 IAS 2011 Rome, Italy Charles S Mgone EDCTP Executive Director.
© IFPMA 2009 IFPMA to WHO EWG 12 Jan 09 1 Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009 IFPMA Presentation.
WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.
Research Leaders: Meeting the challenge Mark Walport 19 November 2008.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
Ensuring Access to Data and Information - Capacity Building for Tropical Diseases Lester Chitsulo Special Programme for Research and Training in Tropical.
Alessandro de Luca Senior Vice President MERCK Group
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
Pharmacovigilance Shanthi Pal, M.Pharmacy, PhD
6 th Annual Emergency Plan for AIDS Relief Track 1.0 ART Program Meeting August 11–12, 2008; Washington D.C. Christian Pitter, MD MPH Director, Global.
Working Together to Improve Global Health
WHO-Technical Briefing Seminar | 03 November 2010 Gilles Forte 1 |1 | WHO Technical Briefing Seminar Geneva November WHO Collaboration with.
USAID Neglected Tropical Diseases Program. 2 WHO 17 Neglected Tropical Diseases (NTDs) by Strategic Interventions London Declaration 10 NTDs USAID 5 NTDs.
9.3 Equations as Relations CORD Math Mrs. Spitz Fall 2006.
Promoting patient-centred healthcare around the world Advancing the fight against counterfeit medicines Ms. Regina Kamoga IAPO Board Member, Country Manager,
1 RA III - Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Buenos Aires, Argentina, 25 – 27 October 2006 Status of observing programmes in RA.
1 RA I Sub-Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Casablanca, Morocco, 20 – 22 December 2005 Status of observing programmes in RA I.
Scientific organizations that agree that humans are changing the climate American Academy of Pediatrics American Association for the Advancement of.
Geneva, Switzerland, September 2012
DOING GOOD IN THE WORLD. Doing Good in the World | 2 OUR MISSION World Understanding Goodwill Peace.
THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.
7/16/08 1 New Mexico’s Indicator-based Information System for Public Health Data (NM-IBIS) Community Health Assessment Training July 16, 2008.
1 WHO Programme for International Drug Monitoring : ensuring the safety of medicines Dr Mary Couper & Dr Shanthi Pal Quality Assurance and Safety: Medicines.
European and Developing Countries Clinical Trials Partnership AEMI Seminar Dec 2010 Dr Thomas Nyirenda South-South Networking and Capacity Development.
National Scorecard, 2008: Chartpack This Chartpack presents data for all indicators scored in the National Scorecard on U.S. Health System Performance,
What is HMN? Global partnership founded on the premise that better health information means better decisions and better health Partners reflect wide.
SAVING LIVES AND CREATING IMPACT EU investment in poverty-related neglected diseases.
OCTOBER 2014 TREATMENT ACTION GROUP MIKE FRICK. Annual Global Plan Research Funding Targets versus 2013 Funding $600,000,000 $800,000,000 $400,000,000.
Food for Education and the Essential Package for School-age Children Flora Sibanda-Mulder Senior Advisor UNICEF/WFP Collaboration 21 July 2005.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
Benefits of Family Planning
Development, utilisation and retention of capacity for clinical research in sub-Saharan Africa 19 July 2011 IAS 2011 Rome, Italy Charles S Mgone EDCTP.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
SCI’s contribution to the global effort to control and eliminate schistosomiasis Dr Wendy Harrison 26 th June 2014.
Child Friendly Cities Initiative
25 seconds left…...
Polio Eradication Although the number of endemic countries is at an all-time low in 2002, the actual number of cases was approximately four times higher.
Global Forum on Bioethics in Research International Research Ethics Training Program Directors Network Meeting Bethesda, USA, October, 16-17, 2007 Sandra.
Nutrition/HIV – new developments Increased Evidence Base – e.g. micronutrient supplements, RUTF High Profile Meetings – Durban, Blantyre. Others planned.
Family Health International Kenneth F. Schulz, PhD, MBA Science for Global Action and Impact.
UNDP Regional Bureau for Africa MDG-based national Development Planning Training Workshop HIV/AIDS Assessments Dar Es Salaam February 27 - March 3, 2006.
UNDP RBA Workshop on MDG-Based National Development Strategies Module 4: Health Strategies UN Millennium Project February 27-March 3, 2006.
Why was the guide written? How is the Guide organized?
Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical.
Global Alliance for Vaccines and Immunization. n An Alliance u Traditional and new partners u Public and private sector n Partners have in common: u Situation.
Elaine Ireland Global Health Advocacy Officer, International HIV/AIDS Alliance Rome, 9 th February Delivering Effective Aid for Health: International Health.
© 2017 SlidePlayer.com Inc. All rights reserved.